ArticleScientific reports2026
Estimating major pathological response in non-small cell lung cancer patients with post-neoadjuvant therapy using MMT-net.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Neoadjuvant therapy (NAT) has demonstrated considerable effectiveness in treating locally advanced non-small cell lung cancer (NSCLC). Major pathological response (MPR), defined by the proportion of viable tumor cells in the tumor bed assessed through whole slide images (WSIs), is regarded as a crucial marker for predicting patient prognosis. While artificial intelligence (AI)-assisted WSI analysis has proven to be more effective than manual inspection, the intricate nature of analyzing post-NAT NSCLC WSIs still poses substantial clinical and computational challenges. In this study, we introduce a self-supervised learning model named the Multi-Magnifier Transformer Network (MMT-Net), designed for estimating MPR in NSCLC patients with post-NAT. The MMT-Net framework comprises three main components: a CNN backbone pretrained on unannotated pathological images for feature extraction, a multi-attention mechanism for fusing multi-scale features and a transformer layer for final classification. Validation results on the curated NSCLC post-NAT dataset have demonstrated that MMT-Net is more effective than commonly used methods for estimating MPR. Additionally, attention map visualizations show strong agreement with pathologist annotations, and the model outputs significantly correlate with immunohistochemistry markers such as CK and Ki67, confirming the reliability of MMT-Net. The proposed MMT-Net holds promise for improving the efficiency of MPR estimation, further advancing the clinical application of NAT in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.